Found on pharmacist.com
Group by:
Title Date Type
APhA-APPM Special Interest Groups (SIGs)
The APhA-APPM SIGs are member-driven groups focused on key areas of interest. Many SIGs have committees and work groups where APhA members can create resources, provide webinars, and work on other projects to help other APhA members in their pharmacy practices. Each SIG has its own community on the…
Jul 10, 2012 Basic page
Medical Home/ACO SIG
APhA Engage Medical Home/ACO SIG Community Mission The mission of the Medical Home/ACO SIG is to facilitate a network of practitioners, administrators, and educators who share an interest in the development, implementation, and dissemination of information regarding new models for patient…
Jun 18, 2013 Basic page
Preceptor SIG
APhA ENGAGE Preceptor SIG Community Mission To create a professional network of pharmacists who share an interest in any or all aspects of precepting student pharmacists and/or pharmacy residents. Purpose To create an interactive community where pharmacists who precept students and…
Apr 29, 2013 Basic page
Partners Which Host APhA Programs
Many APhA certificate training programs are offered under license agreements with other organizations, such as state pharmacy associations, colleges and universities, and pharmacy chains. This agreement allows the organization to host the APhA certificate training programs. To Register for a…
Feb 05, 2018 Basic page
FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults
FDA News Release (05/16/18)
FDA approved on Wednesday lofexidine hydrochloride (Lucemyra—US WorldMeds) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. The agency noted that although the drug may reduce the severity of withdrawal symptoms, it may not prevent them…
May 16, 2018 Publication Pharmacy Today Daily Edition
Inhaled combined budesonide-formoterol as needed in mild asthma
New England Journal of Medicine (05/17/18) Vol. 378, No. 20, P. 1865 O'Byrne, Paul M.; FitzGerald, J. Mark; Bateman, Eric D.; et al.
For patients with mild asthma, using as-needed budesonide–formoterol provided superior asthma symptom control compared with as-needed terbutaline, according to new research, but it was inferior to maintenance therapy with budesonide. The 52-week trial randomized more than 3,800 patients aged…
May 16, 2018 Publication Pharmacy Today Daily Edition
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA
New England Journal of Medicine (05/16/18) Johnston, S. Claiborne; Easton, J. Donald; Farrant, Mary; et al.
Researchers assembled a large, multinational cohort to test whether a combination antiplatelet therapy that successfully reduced the odds of recurrent stroke in Chinese patients would also benefit others. For the POINT trial, 2,432 patients with minor ischemic stroke or high-risk transient ischemic…
May 16, 2018 Publication Pharmacy Today Daily Edition
For women with early breast cancer, trastuzumab treatment can be much shorter
New York Times (05/16/18) Grady, Denise
The results of a large, new study involving thousands of women with early-stage breast cancer for a median of more than 5 years indicate that women who received 6 months of trastuzumab (Herceptin—Genentech) did just as well as those who received it for 12 months. There were also fewer adverse…
May 16, 2018 Publication Pharmacy Today Daily Edition
Effect of fremanezumab compared with placebo for prevention of episodic migraine
Journal of the American Medical Association (05/15/18) Vol. 319, No. 19, P. 1999 Dodick, David W.; Silberstein, Stephen D.; Bigal, Marcelo E.; et al.
Researchers recruited 875 adults with episodic migraine to evaluate the prevention power of subcutaneous fremanezumab. Patients who previously received no relief from two or more classes of migraine-preventive medication were disqualified from the multinational study. Eligible participants were…
May 16, 2018 Publication Pharmacy Today Daily Edition
After outcry, drugmakers decide not to triple the price of a cancer medication
Washington Post (05/15/18) Johnson, Carolyn Y.
Two drug companies that jointly sell the blood cancer drug ibrutinib (Imbruvica—Janssen/Pharmacyclics) have reversed their decision to effectively triple its cost. Janssen and Pharmacyclics recently announced they were discontinuing the old capsule and introducing once-a-day tablets in four…
May 16, 2018 Publication Pharmacy Today Daily Edition